ERBB2 and breast carcinoma: Furthermore, the potential of T-DXd is being examined in combination with durvalumab (an anti-PD-L1 agent, NCT04538742) and tucatinib (a tyrosine kinase inhibitor targeting HER2, NCT04538742 and NCT04539938) in metastatic HER2+ breast cancer.